New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency

European Journal of Immunology

Volumn 35, Issue 1, 2005, Pages 25-30

  Hershfield, Michael S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adenosine; Adenosine receptors; cAMP; Deoxyadenosine; SCID

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE DEAMINASE; ADENOSINE KINASE; ADENOSINE RECEPTOR; ADENOSYLHOMOCYSTEINASE; ADENYLATE CYCLASE; DEOXYADENOSINE; DEOXYCYTIDINE KINASE; FOLINIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; METHOTREXATE; NUCLEOSIDE TRANSPORTER; PENTOSTATIN; S ADENOSYLHOMOCYSTEINE; THYMIDINE;

ADENOSINE DEAMINASE DEFICIENCY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; COMBINED IMMUNODEFICIENCY; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG POTENCY; ENZYME DEFICIENCY; ENZYME INHIBITION; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; LYMPHOID CELL; NONHUMAN; NUCLEIC ACID METABOLISM; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; T LYMPHOCYTE;

ADENOSINE; ADENOSINE DEAMINASE; ANIMALS; DEOXYADENOSINES; HUMANS; IMMUNE TOLERANCE; INFANT; LYMPHOCYTES; MICE; MICE, KNOCKOUT; MODELS, IMMUNOLOGICAL; RECEPTORS, PURINERGIC P1; SEVERE COMBINED IMMUNODEFICIENCY;

EID: 12344281073     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200425738     Document Type: Article

References (40)

1. Buckley, R. H., Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu. Rev. Immunol. 2004. 22: 625-655.
2. Hershfield, M. S., Combined immune deficiencies due to purine enzyme defects. In Stiehm, E. R., Ochs, H. D. and Winkelstein, J. A. (Eds.) Immunologic Disorders in Infants and Children, 5th Edn. W. B. Saunders, Philadelphia 2004, pp 480-504.
3. Hershfield, M. S. and Mitchell, B. S., Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In Scriver, C. R., Beaudet, A. L., Sly, W. S. and Valle, D. (Eds.) The Metabolic and Molecular Bases of Inherited Disease, 8th Edn. McGraw-Hill, New York 2001, pp 2585-2625.
4. Fredholm, B. B., Ijzerman, A. P., Jacobson, K. A., Klotz, K.-N. and Linden, J., International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 2001. 53: 527-552.
5. Hasko, G. and Cronstein, B. N., Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 2004. 25: 33-39.
6. Sitkovsky, M. V., Lukashev, D., Apasov, S., Kojima, H., Koshiba, M., Caldwell, C., Ohta, A. and Thiel, M., Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu. Rev. Immunol. 2004. 22: 657-682.
7. Yang, J. C. and Cortopassi, G. A., dATP causes specific release of cytochrome C from mitochondria. Biochem. Biophys. Res. Commun. 1998. 250: 454-457.
8. Zou, H., Li, Y., Liu, X. and Wang, X., An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J. Biol. Chem. 1999. 274: 11549-11556.
9. Purring-Koch, C. and McLendon, G., Cytochrome c binding to apaf-1: the effects of dATP and ionic strength. Proc. Natl. Acad. Sci. USA 2000. 97: 11928-11931.
10. Arredondo-Vega, F. X., Santisteban, I., Daniels, S., Toutain, S. and Hershfield, M. S., Adenosine deaminase deficiency: genotype-phenotype correlations based on expressed activity of 29 mutant alleles. Am. J. Hum. Genet. 1998. 63: 1049-1059.
11. Hirschhorn, R., Immunodeficiency disease due to deficiency of adenosine deaminase. In Ochs, H. D., Smith, C. I. E. and Puck, J. M. (Eds.) Primary Immunodeficiency Diseases. A Molecular and Genetic Approach. Oxford University Press, New York 1999, pp 121-139.
12. Minguet, S., Huber, M., Rosenkranz, L., Schamel, W. W. A., Reth, M. and Brummer, T., Adenosine and cAMP are potent inhibitors of the NF-κB pathway downstream of immunoreceptors. Eur. J. Immunol. 2005. 35: http://dx.doi.org/10.1002/eji.200425524, this issue.
13. Olah, M. E. and Stiles, G. L., Adenosine receptor-mediated signal transduction. In Pelleg, A. and Belardinelli, L. (Eds.) Effects of Extracellular Adenosine and ATP on Cardiomyocytes. R.G. Landes, Austin, TX, USA 1998, pp 1-31.
14. Fredholm, B. B., Irenius, E., Kull, B. and Schulte, G., Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem. Pharmacol. 2001. 61: 443-448.
15. Koshiba, M., Rosin, D. L., Hayashi, N., Linden, J. and Sitkovsky, M. V., Patterns of A2A extracellular adenosine receptor expression in different functional subsets of human peripheral T cells. Flow cytometry studies with anti-A2A receptor monoclonal antibodies. Mol. Pharmacol. 1999. 55: 614-624.
16. Lukashev, D. E., Smith, P. T., Caldwell, C. C., Ohta, A., Apasov, S. G. and Sitkovsky, M. V., Analysis of A2a receptor-deficient mice reveals no significant compensatory increases in the expression of A2b, A1, and A3 adenosine receptors in lymphoid organs. Biochem. Pharmacol. 2003. 65: 2081-2090.
17. Genestier, L., Paillot, R., Fournel, S., Ferraro, C., Miossec, P. and Revillard, J. P., Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J. Clin. Invest. 1998. 102: 322-328.
18. Gerondakis, S. and Strasser, A., The role of Rel/NF-κB transcription factors in B lymphocyte survival. Semin. Immunol. 2003. 15: 159-166.
19. Kucharczak, J., Simmons, M. J., Fan, Y. and Gelinas, C., To be, or not to be: NF-κB is the answer - role of Rel/NF-κB in the regulation of apoptosis. Oncogene 2003. 22: 8961-8982.
20. Ruland, J. and Mak, T. W., From antigen to activation: specific signal transduction pathways linking antigen receptors to NF-κB. Semin. Immunol. 2003. 15: 177-183.
21. Hayden, M. S. and Ghosh, S., Signaling to NF-κB. Genes Dev. 2004. 18: 2195-2224.
22. Aldrich, M. B., Chen, W., Blackburn, M. R., Martinez-Valdez, H., Datta, S. K. and Kellems, R. E., Impaired germinal center maturation in adenosine deaminase deficiency. J. Immunol. 2003. 171: 5562-5570.
23. Majumdar, S. and Aggarwal, B. B., Adenosine suppresses activation of nuclear factor-κB selectively induced by tumor necrosis factor in different cell types. Oncogene 2003. 22: 1206-1218.
24. Lukashev, D., Ohta, A., Apasov, S., Chen, J. F. and Sitkovsky, M., Cutting edge: Physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo. J. Immunol. 2004. 173: 21-24.
25. Zhang, H., Conrad, D. M., Butler, J. J., Zhao, C., Blay, J. and Hoskin, D.W., Adenosine acts through A2 receptors to inhibit IL-2-induced tyrosine phosphorylation of STAT5 in T lymphocytes: role of cyclic adenosine 3′,5′-monophosphate and phosphatases. J. Immunol. 2004. 173: 932-944.
26. Apasov, S., Chen, J. F., Smith, P. and Sitkovsky, M., A(2A) receptor dependent and A(2A) receptor independent effects of extracellular adenosine on murine thymocytes in conditions of adenosine deaminase deficiency. Blood 2000. 95: 3859-3867.
27. Apasov, S. G. and Sitkovsky, M. V., The extracellular versus intracellular mechanisms of inhibition of TCR-triggered activation in thymocytes by adenosine under conditions of inhibited adenosine deaminase. Int. Immunol. 1999. 11: 179-189.
28. Apasov, S. G., Blackburn, M. R., Kellems, R. E., Smith, P. T. and Sitkovsky, M. V., Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signaling. J. Clin. Invest. 2001. 108: 131-141.
29. Wakamiya, M., Blackburn, M. R., Jurecic, R., McArthur, M. J., Geske, R. S., Cartwright, J. Jr., Mitani, K., Vaishnav, S., Belmont, J. W., Kellems, R. E. et al., Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice. Proc. Natl. Acad. Sci. USA 1995. 92: 3673-3677.
30. Migchielsen, A. A., Breuer, M. L., van Roon, M. A., te Riele, H., Zurcher, C., Ossendorp, F., Toutain, S., Hershfield, M. S., Berns, A. and Valerio, D., Adenosine deaminase-deficient mice die perinatally and exhibit liver-cell degeneration, atelectasis and small intestinal cell death. Nat. Genet. 1995. 10: 279-287.
31. Blackburn, M. R., Datta, S. K. and Kellems, R. E., Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency. J. Biol. Chem. 1998. 273: 5093-5100.
32. Blackburn, M. R., Aldrich, M., Volmer, J. B., Chen, W., Zhong, H., Kelly, S., Hershfield, M., Datta, S. K. and Kellems, R. E., The use of enzyme therapy to regulate the metabolic and phenotypic consequences of adenosine deaminase deficiency in mice: differential impact on pulmonary and immunologic abnormalities. J. Biol. Chem. 2000. 275: 32114-32121.
33. Thompson, L. F., Van De Wiele, C. J., Laurent, A. B., Hooker, S. W., Vaughan, J. G., Jiang, H., Khare, K., Kellems, R. E., Blackburn, M. R., Hershfield, M. S. and Resta, R., Metabolites from apoptotic thymocytes inhibit thymopoiesis in adenosine deaminase-deficient fetal thymic organ cultures. J. Clin. Invest. 2000. 106: 1149-1157.
34. Van De Wiele, C. J., Vaughn, J. G., Blackburn, M. R., Ledent, C. A., Jacobson, M., Jiang, H. and Thompson, L. F., Adenosine kinase inhibition promotes survival of fetal adenosine deaminase-deficient thymocytes by blocking dATP accumulation. J. Clin. Invest. 2002. 110: 395-402.
35. Blackburn, M. R., Too much of a good thing: adenosine overload in adenosine-deaminase-deficient mice. Trends Pharmacol. Sci. 2003. 24: 66-70.
36. Tilley, S. L., Tsai, M., Williams, C. M., Wang, Z. S., Erikson, C. J., Galli, S. J. and Koller, B. H., Identification of A3 receptor- and mast cell-dependent and -independent components of adenosine-mediated airway responsiveness in mice. J. Immunol. 2003. 171: 331-337.
37. Young, H. W., Molina, J. G., Dimina, D., Zhong, H., Jacobson, M., Chan, L. N., Chan, T. S., Lee, J. J. and Blackburn, M. R., A3 adenosine receptor signaling contributes to airway inflammation and mucus production in adenosine deaminase-deficient mice. J. Immunol. 2004. 173: 1380-1389.
38. Moser, G. H., Schrader, J. and Deussen, A., Turnover of adenosine in plasma of human and dog blood. Am. J. Physiol. 1989. 256: C799-C806.
39. Hershfield, M. S., Kredich, N. M., Koller, C. A., Mitchell, B. S., Kurtzberg, J., Kinney, T. R. and Falletta, J. M., S-Adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2′-deoxycoformycin alone and in combination with 9-β-D-arabinofuranosyladenine. Cancer Res. 1983. 43: 3451-3458.
40. Hershfield, M. S., Kurtzberg, J., Moore, J. O., Whang Peng, J. and Haynes, B. F., Conversion of a stem cell leukemia from T-lymphoid to a myeloid phenotype by the adenosine deaminase inhibitor 2′-deoxycoformycin. Proc. Natl. Acad. Sci. USA 1984. 81: 253-257.